A Phase 1 interventional study of Adenosine 5'-triphosphate in Chronic Cough (CC) and Asthma, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by McMaster University · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Chronic Cough with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Chronic Cough · Canada.
Among the 22 studies in Chronic Cough with a site in Canada, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1, and was the 20th registered.
142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.
Browse Chronic Cough studies →7 of the 22 studies in Chronic Cough with a site in Canada are open now. Recruiting first, the newest first:
Trevi Therapeutics · Sites in Canada, United Kingdom
Ages 18+
McMaster University · Sites in Canada
Ages 18+ · Healthy volunteers
McMaster University · Sites in Canada
Ages 18+
McMaster University · Sites in Canada
Ages 18–80 · Healthy volunteers
West Park Healthcare Centre · Sites in Canada
Ages 18–85
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5 · Phase 4 2
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 33 is below the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 122 across the 18 interventional studies, 170 across the 4 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 7 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Cough with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05086432McMaster UniversitySputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD | 2027-03 |
| NCT07671924Trevi TherapeuticsThe Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Chronic Cough with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.
Phase 1: Healthy individuals
Inclusion Criteria:
Eligible participants in Phase 1 will include healthy adults (≥18 years old) with:
Exclusion Criteria:
We will exclude healthy individuals meeting the following:
(1) Are a current or former smoker with a >5 pack-year history and abstinence ≤6 months;
Women of who:
Phase 2: Patients with RCC/UCC and mild- naïve asthma
Inclusion Criteria:
Eligible participants will include adults (≥18 years old) with:
RCC/UCC for >1 year, demonstrated by a normal chest radiograph and no airflow obstruction (/FVC>0.7/LLN) with either:
Exclusion Criteria:
Cohort-specific exclusion criteria include the following:
For the RCC/UCC cohort:
(1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months;
For the mild steroid-naïve asthma cohort:
We will exclude participants meeting any of the following criteria from the study:
Female participants of child-bearing potential who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Adenosine 5'-triphosphate
Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
The mean %FEV1 change from baseline at incremental doses of ATP
Time frame: Until the end of the ATP cough challenge
Symptoms of wheeze measured on the mBorg scale at incremental doses of ATP
Time frame: Until the end of the ATP cough challenge
Symptoms of chest tightness measured on the mBorg scale at incremental doses of ATP
Time frame: Until the end of the ATP cough challenge
Symptoms of shortness of breath measured on the mBorg scale at incremental doses of ATP
Time frame: Until the end of the ATP cough challenge
The mean change in oxygen saturations (SpO2) from baseline at incremental doses of ATP
Time frame: Until the end of the ATP cough challenge
The intra-class correlation of measures obtained from repeat ATP cough challenges
Time frame: Baseline to 1 week
The frequency of adverse events
Time frame: Baseline to 1 week
Total maximum number of evoked coughs (Emax) by any dose of ATP
Time frame: Until the end of the ATP cough challenge
The dose of ATP that induces at least 50% of the maximal cough response (ED50)
Time frame: Until the end of the ATP cough challenge
The dose of ATP that induces at least 5 coughs (C5)
Time frame: Until the end of the ATP cough challenge
The dose of ATP that induces at least 2 coughs (C2)
Time frame: Until the end of the ATP cough challenge
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adenosine Triphosphate